CPhI 2022, November 1-3
-
eikon
-
26 Ottobre 2022
-
NEWS
-
0 Comments
Are we going to be present at the next CPhI in Frankfurt? We are, of course! For three days, from November 1st to 3rd, we have the opportunity to reaffirm the identity of the company and meet professionals from many different countries. As if it were not enough, we will introduce our last reason of pride: the brand new PolyCrystalLine …
Continue Reading
CF@BO 2021, September 10 – 11
-
eikon
-
17 Ottobre 2022
-
NEWS
-
0 Comments
ABOUT THE CH@BO n.11 ONLINE CONVENTION Because of the uncertainties still associated with the pandemic of SARS-COVID-19 the 11th edition of the Bologna Convention on Crystal Forms CF@Bo n. 11 will take place in online mode. As in the past occasions the meeting will bring together, albeit in virtual mode, academic and industrial experts interested in sharing experience and discussing …
Continue Reading
PolyCrystalLine attending CPhI 2021 in Milan!
-
admin
-
17 Ottobre 2022
-
NEWS
-
0 Comments
Meet us at the forthcoming CPhI 2021 in Milan, from November 9 to November 11. We will be at booth, 4H93, to introduce the latest development of our Company.
Continue Reading
PolyCrystalLine CDMO is on the way
-
admin
-
17 Ottobre 2022
-
NEWS
-
0 Comments
The construction work of the new facility started in Mesagne (BR), Puglia in June 2021.
Continue Reading
Render of PolyCrystalLine CDMO
-
admin
-
17 Ottobre 2022
-
NEWS
-
0 Comments
This is the render of PolycrystalLine’s new facility, dedicated to the new CDMO services, that will be located in Mesagne (BR), Puglia.
Continue Reading
Des-Methyl-Venlafaxine Salt
-
eikon
-
16 Ottobre 2022
-
NEWS
-
0 Comments
New Crystalline Forms of Des-Methyl-Venlafaxine Salt Discovered PolyCrystalLine s.r.l. and Segrub Pharmaceuticals have developed a generic equivalent to Pristiq (desvenlafaxine succinate). This DEP001 product is expected to enter the US market at least three years before any other generic desvenlafaxine products enter the market. Pristiq sales are projected to exceed one billion dollars yearly. Pristiq was approved in 2008 by Wyeth Pharmaceuticals for the treatment …
Continue Reading
IMAZAMOX: A Quest for Polymorphic Modifications of a Chiral and Racemic Herbicid
-
eikon
-
15 Ottobre 2022
-
NEWS
-
0 Comments
ABSTRACT: The structure−property relationships of new polymorphs of the chiral herbicide imazamox were investigated by X-ray diffraction, hot stage microscopy (HSM), and differential scanning calorimetry (DSC). Four different polymorphs of imazamox(R) were found. The relationship between different crystal forms, relative thermal stability, and possible conversions pathways was explored. Racemic imazamox, for which no polymorphic modifications could be observed, was also characterized …
Continue Reading
Join us at CPhI Worldwide – Milan 2021
-
eikon
-
14 Ottobre 2022
-
NEWS
-
0 Comments
We invite you to join us at our booth n. 4H93 and learn more about our capabilities: In order to schedule a meeting please contact marco.glucini@polycrystalline.it
Continue Reading
Meet us at DCAT in New York!
-
eikon
-
13 Ottobre 2022
-
NEWS
-
0 Comments
We invite you to join us in our meeting room at the Intercontinental Suite #510/511 and learn more about our capabilities: In order to schedule a meeting please contact luca.covello@polycrystalline.it.
Continue Reading
Polymorphs of Dex-Lansoprazole
-
eikon
-
8 Ottobre 2022
-
NEWS
-
0 Comments
New Crystalline Forms of Dex-Lansoprazole Discovered PolyCrystalLine s.r.l. and Segrub Pharmaceuticals have developed a generic equivalent to Kapidex (dexlansoprazole). This DEP002 product contains a new and stable crystal of dexlansoprazole which circumvents Takeda’s intellectual property. Kapidex is a proton pump inhibitor that obtained FDA approval in 2009 by Takeda Pharmaceuticals for the treatment of heartburn associated with symptomatic non-erosive gastroesophageal reflux disease …
Continue Reading
Commenti recenti